ASRT vs BFRI

Assertio Holdings, Inc. vs Biofrontera Inc. — Valuation Comparison 2026

ASRT

Drug Manufacturers - Specialty & Generic
Assertio Holdings, Inc.
Quality
5.4
out of 10
Value Trap
24
SAFE
Price
$23.44
Last close
Models
10/13
Active
VS

BFRI

Drug Manufacturers - Specialty & Generic
Biofrontera Inc.
Quality
5.6
out of 10
Value Trap
30
LOW
Price
$0.86
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ASRT Fair ValueASRT Upside BFRI Fair ValueBFRI Upside
Bayesian DCF Intrinsic $50.65 +116.1% $0.38 -55.8%
First Chicago Scenario $76.95 +228.3%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $19.55 -16.6% $1.72 +99.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASRT vs BFRI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASRT vs BFRI — Which Stock Is More Undervalued?

BFRI scores higher with a 5.6/10 quality rating vs ASRT's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Assertio Holdings, Inc. (ASRT) and Biofrontera Inc. (BFRI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASRT currently trades at $23.44 with a QOC of 5.4/10, while BFRI trades at $0.86 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).